Azaya Launches CDMO Unit

Azaya Therapeutics Inc., an oncology company focused on developing cancer treatments through its nanotechnology platform, has launched Parexo Labs, a CDMO providing chemical testing and liposomal manufacturing services to outside organizations.

Parexo Labs will leverage Azaya’s capabilities in cytotoxic and nanoparticle analysis and liposome manufacturing, including its proprietary analytical methodology to detail release rates and characterization attributes of nanoparticles. Parexo Labs offers lab services that can speed drug development and regulatory progress for pharmaceutical and medical device developers alike, according to a company statement.

“Azaya Therapeutics has more than 10 years of experience in the cytotoxic and nanotechnology arenas, which we are now leveraging with the rollout of Parexo Labs,” said Mike Dwyer, chief executive officer and president of Azaya Therapeutics. “Through Parexo, we can apply these analytical capabilities and development methodologies to organizations in need of them for their own development programs.”

“Chemotherapy and nanotechnology continue to be at the forefront of cancer treatment options,” commented Don Kruppa, Azaya Therapeutics’ vice president, Operations. “Building on Azaya’s drug development and manufacturing expertise, Parexo Labs can offer both commercial and academic customers innovative solutions in nanoparticle characterization and analysis, as well as the latest nanoparticle testing technology.”

Parexo Labs services cover method development and validation for cytotoxics, as well as raw material testing, stability storage and testing, chemical characterization and other analyses. Parexo also provides customized liposome manufacturing services, based on its proprietary nanoparticle release methodology, to meet customers’ academic or commercial needs, according to a press statement.